TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03979547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down.
Study: NCT00135785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03965221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LYNX
Description: Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChoices
Description: Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
Study: NCT04318314

Intervention type: DIAGNOSTIC_TEST
Intervention: COPAN swabbing and blood sample collection
Description: COPAN swabbing of nostrils and/or oropharynx and blood sample collection
Study: NCT02068378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMPE Optical Sensor Device
Description: Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
Study: NCT01674452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based group (HBG)
Description: Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised exercise group (SEG)
Description: Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
Study: NCT01032356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study: NCT04107181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Introducer calla device
Description: The research introducer will be used after the patient consents prior to the annual pap smear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews only
Description: Healthy volunteer interviews
Study: NCT00691678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin
Description: 400mg chondroitin three times a day (TID) for twenty-four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine
Description: 500mg glucosamine TID for twenty-four weeks
Study: NCT02872519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Laboratory Biomarker Analysis
Study: NCT01817712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement & Support
Description: IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Transitional Work Program
Description: The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role.
Study: NCT05372471

Intervention type: OTHER
Group type: OTHER
Intervention: mHealth
Description: ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
Study: NCT02348372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A Placebo
Description: Matching size, shape and color

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863A Placebo
Description: Matching size, shape and color

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet
Study: NCT02804867

Intervention type: PROCEDURE
Intervention: Online questionnaire and self-administered blood spot

Intervention type: PROCEDURE
Intervention: Online questionnaire and self-administered blood spot

Intervention type: PROCEDURE
Intervention: Online questionnaire and self-administered blood spot
Study: NCT01573754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 100 mg by mouth twice weekly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: 450 mL every 2 weeks
Study: NCT04392830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ002 DS
Description: Administered orally
Study: NCT02348372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet
Study: NCT04392830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03012763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Oral administration of 250 mg paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Oral administration of 250 mg paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Oral administration of 250 mg paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Oral administration of 50 mg sulfasalazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Oral administration of 50 mg sulfasalazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: Oral administration of 50 mg sulfasalazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Oral administration of 120 mg fexofenadine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Oral administration of 120 mg fexofenadine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexofenadine
Description: Oral administration of 120 mg fexofenadine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Oral administration of 40 mg valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Oral administration of 40 mg valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan
Description: Oral administration of 40 mg valsartan

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-caloric water
Description: Oral administration of 240 ml non-caloric water
Study: NCT02348372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet
Study: NCT04599907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roll-In Cohort: Single Application of N-SWEAT Patch
Description: Single Application of N-SWEAT Patch in both axillae for 10 subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Randomized Cohort: Single Application of N-SWEAT Patch
Description: Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Randomized Cohort: Single Application of Sham Patch
Description: Single Application of Sham Patch in both axillae for subjects randomized to the control group
Study: NCT03012763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caloric drink
Description: Oral administration of 240 ml caloric drink

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: grapefruit juice
Description: Oral administration of 240 ml grapefruit juice
Study: NCT01466517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium®
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
Study: NCT04739332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Newborn behavioral observations system
Description: The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
Study: NCT04342988

Intervention type: DRUG
Group type: OTHER
Intervention: Cequa
Description: The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
Study: NCT02187445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Description: To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
Study: NCT00977795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
Study: NCT02864199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
Study: NCT04630470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage therapy with lavender oil
Description: massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: massage therapy with baby oil
Description: massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
Study: NCT02579278

Intervention type: OTHER
Intervention: Blood sample (mrEMVI positive patient)
Description: Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.

Intervention type: OTHER
Intervention: Blood sample (mrEMVI negative patient)
Study: NCT06276114

Intervention type: DEVICE
Intervention: Stent Underexpansion
Description: Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.

Intervention type: DEVICE
Intervention: Stent Underexpansion
Description: Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
Study: NCT04684771

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MYOSTIM®
Description: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Bars with no active ingredient and the same flavor (chocolate and red fruits).
Study: NCT00494208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester
Study: NCT03134274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dip HBDA
Description: Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
Study: NCT01612221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
Study: NCT02872818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17β estradiol hemihydrate
Description: 4mg/kg/day for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17β estradiol hemihydrate
Description: 4mg/kg/day for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17β estradiol hemihydrate
Description: 4mg/kg/day for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 50 mg/kg/day last 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: 1mg/kg/day last 10 days
Study: NCT03146754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methodology
Description: No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methodology
Description: No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
Study: NCT03098797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 40 mg daily subcutaneous injection for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elamipretide
Description: 40 mg daily subcutaneous injection for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: daily subcutaneous injection for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily subcutaneous injection for 12 weeks
Study: NCT04410315

Intervention type: OTHER
Intervention: Serum-lactate < 2,2 mmol/L
Description: Bloodgas analysis every hour from start surgery until recovery ward discharge

Intervention type: OTHER
Intervention: Serum-lactate >/= 2,2 mmol/L
Description: Bloodgas analysis every hour from start surgery until recovery ward discharge
Study: NCT00761397

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises

Intervention type: BEHAVIORAL
Intervention: Phone Call
Description: Phone call follow ups for 4 weeks after last radiation treatment

Intervention type: OTHER
Intervention: Brochure
Description: Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises

Intervention type: OTHER
Intervention: Questionnaire
Description: Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
Study: NCT03090633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: Minimally invasive in-utero surgery
Study: NCT04251962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: epidural solution containing bupivacaine 0.1% in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: epidural solution containing bupivacaine 0.1% in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
Study: NCT02921750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber Gelling Fibre Dressing
Description: Gelling fibre dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre
Description: Hydrofiber® Dressing with Strengthening Fibre
Study: NCT00990067

Intervention type: DRUG
Group type: OTHER
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg, single dose
Study: NCT00761397

Intervention type: OTHER
Intervention: Questionnaire
Description: Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
Study: NCT00990067

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: 120 mg two doses 12h and 2h before MDMA

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: capsules identical to MDMA or duloxetine
Study: NCT02638129

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone HCl/Bupropion HCl ER
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone HCl/Bupropion HCl ER
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl/Bupropion HCl ER
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets
Study: NCT03648554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulaglutide (TRULICITY®) 1.5 mg
Description: dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reinforced dietary monitoring
Description: moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: reinforced dietary monitoring
Description: moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
Study: NCT03099772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-IU
Description: Cognitive-behavioral therapy for intolerance of uncertainty
Study: NCT04427137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
Description: Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.